AIP
HBIO icon

ARS Investment Partners’s Harvard Bioscience HBIO Stock Holding History

ARS Investment Partners’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,118
Closed -$157K – 116
2019
Q3 		$157K Hold
5,118
– – 0.03% 105
2019
Q2 		$102K Buy
5,118
+2
+0% +$59 0.02% 133
2019
Q1 		$220K Sell
5,116
-11,312
-69% -$410K 0.04% 108
2018
Q4 		$522K Sell
16,428
-16,347
-50% -$644K 0.11% 92
2018
Q3 		$1.72M Buy
32,775
+237
+0.7% +$13.3K 0.27% 68
2018
Q2 		$1.74M Buy
32,538
+3,010
+10% +$154K 0.28% 60
2018
Q1 		$1.48M Buy
29,528
+26,803
+984% +$1.2M 0.18% 82
2017
Q4 		$90K Buy
+2,725
New +$92K 0.01% 155

Other funds holding HBIO

ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

ARS Investment Partners's HBIO Position: Q4 2019 in Review

ARS Investment Partners sold out of Harvard Bioscience (HBIO) in Q4 2019, closing a stake of 5,118 shares — an estimated $157K sold.

ARS Investment Partners first reported a position in HBIO in Q4 2017 and held it in 8 quarters. The position peaked at $1.74M in Q2 2018. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2019.

  • ARS Investment Partners reported no remaining Harvard Bioscience position as of Q4 2019 after selling out during the quarter.
  • ARS Investment Partners sold 5,118 Harvard Bioscience shares in Q4 2019, an estimated $157K.
  • ARS Investment Partners first reported a position in Harvard Bioscience in Q4 2017 and held it in 8 quarters.
  • ARS Investment Partners's Harvard Bioscience position peaked at $1.74M in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2019.

Based on ARS Investment Partners's 13F filing for Q4 2019, filed 12 Feb 2020.